AR088021A1 - Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica - Google Patents
Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeuticaInfo
- Publication number
- AR088021A1 AR088021A1 ARP110102637A ARP110102637A AR088021A1 AR 088021 A1 AR088021 A1 AR 088021A1 AR P110102637 A ARP110102637 A AR P110102637A AR P110102637 A ARP110102637 A AR P110102637A AR 088021 A1 AR088021 A1 AR 088021A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- formula
- atom
- oxygen atom
- absent
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 6
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
Abstract
Se refiere a los compuestos de fórmula (1). Se refiere igualmente a un procedimiento de preparación de los compuestos de fórmula (1), de las composiciones que los contienen y a su aplicación en terapéutica. Reivindicación 1: Compuesto que responde a la fórmula (1) en la que n es igual a 0, 1; D representa un átomo de oxígeno o un enlace; W representa un de nitrógeno o un grupo -CH-; X¹ representa un átomo de nitrógeno o un grupo -CH=CH-; X² representa un átomo de oxígeno o un átomo de nitrógeno; X³ representa un átomo de oxígeno o un átomo de nitrógeno; siendo uno de X¹, X², X³ diferente de un átomo de nitrógeno, no siendo X² y X³ simultáneamente un átomo de oxígeno; R¹, R² están ausentes o representan, independientemente uno del otro, un átomo de hidrógeno o un grupo alquilo C₁₋₄, R¹ y R² pueden formar con el átomo de carbono al que están unidos un grupo -cicloalquilo C₃₋₁₀-; Y representa un grupo -cicloalquilo C₃₋₁₀-, arilo, ariloxi, estando dichos grupos sustituidos opcionalmente con uno o varios sustituyentes elegidos entre un átomo de halógeno o un grupo alcoxi C₁₋₆; Z¹ está ausente o representa una función -NH-; Z² está ausente o representa un grupo metileno, un grupo de formula (2) ó (3); Z³ está ausente o representa un átomo de oxígeno o un grupo metileno, un grupo de formula (2) ó (3); sabiendo que Z² sólo representa un grupo de fórmula (3) cuando Z³ está presente y representa un grupo de fórmula (3), y recíprocamente, Z² y Z³ forman así un enlace doble; sabiendo que Z² y Z³, cuando están presentes, pueden estar comprendidos en un grupo cicloalquilo; sabiendo que cuando Z³ representa un átomo de oxígeno, Z² representa un grupo metileno, un grupo de fórmula (2); en forma de ácido, de base o de sal de adición a un ácido o a una base.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1056060A FR2963005B1 (fr) | 2010-07-23 | 2010-07-23 | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088021A1 true AR088021A1 (es) | 2014-05-07 |
Family
ID=43416427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102637A AR088021A1 (es) | 2010-07-23 | 2011-07-21 | Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20130137691A1 (es) |
| EP (1) | EP2595970B1 (es) |
| JP (1) | JP2013532655A (es) |
| KR (1) | KR20130041127A (es) |
| CN (1) | CN103201271A (es) |
| AR (1) | AR088021A1 (es) |
| AU (1) | AU2011281173A1 (es) |
| BR (1) | BR112013001534A2 (es) |
| CA (1) | CA2806271A1 (es) |
| FR (1) | FR2963005B1 (es) |
| MX (1) | MX2013000907A (es) |
| RU (1) | RU2013107759A (es) |
| SG (1) | SG187564A1 (es) |
| TW (1) | TW201206442A (es) |
| UY (1) | UY33528A (es) |
| WO (1) | WO2012011081A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX386752B (es) | 2015-09-16 | 2025-03-19 | Metacrine Inc | Agonistas del receptor farnesoide x y usos de los mismos. |
| CN107651722A (zh) * | 2016-07-24 | 2018-02-02 | 天津师范大学 | 基于3‑(5‑甲基‑1,3,4‑噁二唑)吡啶的三氟甲磺酸‑Ag(I)配合物在吸附染料中的应用 |
| CN107662956A (zh) * | 2016-07-28 | 2018-02-06 | 天津师范大学 | 3‑(5‑甲基‑1,3,4‑噁二唑)吡啶配体构筑的六氟磷酸‑Ag(I)配合物在吸附染料中的应用 |
| JP7258763B2 (ja) | 2017-03-15 | 2023-04-17 | メタクリン，インク． | ファルネソイドｘ受容体アゴニストおよびその使用 |
| CA3055990A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| MX2021003110A (es) | 2018-09-18 | 2021-05-13 | Metacrine Inc | Agonistas del receptor x farnesoide y usos de los mismos. |
| WO2021188695A1 (en) | 2020-03-18 | 2021-09-23 | Metacrine, Inc. | Formulations of a farnesoid x receptor agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| GB0427328D0 (en) * | 2004-12-14 | 2005-01-19 | Astrazeneca Ab | Chemical compounds |
| WO2007138304A1 (en) * | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
| DE602007011446D1 (en) * | 2006-05-30 | 2011-02-03 | Astrazeneca Ab | Substituierte 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a-diacylglycerolacyltransferase |
| GB0611507D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| GB0611552D0 (en) * | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
| CN101827842A (zh) * | 2007-08-17 | 2010-09-08 | 阿斯利康(瑞典)有限公司 | 作为dgat抑制剂的噁二唑衍生物 |
| KR20100124771A (ko) * | 2008-03-26 | 2010-11-29 | 다이이찌 산쿄 가부시키가이샤 | 신규 테트라하이드로이소퀴놀린 유도체 |
| US8324385B2 (en) * | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| JP2010132590A (ja) * | 2008-12-03 | 2010-06-17 | Astellas Pharma Inc | オキサジアゾール化合物 |
| AU2009329345A1 (en) * | 2008-12-19 | 2011-06-30 | Astrazeneca Ab | 1,3,4-oxadiazole derivatives and their uses to treat diabetes |
| NZ594244A (en) * | 2009-01-28 | 2013-07-26 | Sanofi Sa | Thiadiazole and oxadiazole derivatives, preparation thereof, and therapeutic use thereof |
| FR2941457A1 (fr) * | 2009-01-28 | 2010-07-30 | Sanofi Aventis | Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique |
| WO2010107768A1 (en) * | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
-
2010
- 2010-07-23 FR FR1056060A patent/FR2963005B1/fr not_active Expired - Fee Related
-
2011
- 2011-07-21 AR ARP110102637A patent/AR088021A1/es unknown
- 2011-07-22 UY UY0001033528A patent/UY33528A/es not_active Application Discontinuation
- 2011-07-22 MX MX2013000907A patent/MX2013000907A/es active IP Right Grant
- 2011-07-22 CN CN2011800456589A patent/CN103201271A/zh active Pending
- 2011-07-22 CA CA2806271A patent/CA2806271A1/en not_active Abandoned
- 2011-07-22 AU AU2011281173A patent/AU2011281173A1/en not_active Abandoned
- 2011-07-22 EP EP11746655.7A patent/EP2595970B1/en active Active
- 2011-07-22 KR KR1020137001709A patent/KR20130041127A/ko not_active Withdrawn
- 2011-07-22 SG SG2013004320A patent/SG187564A1/en unknown
- 2011-07-22 WO PCT/IB2011/053278 patent/WO2012011081A1/en not_active Ceased
- 2011-07-22 JP JP2013520278A patent/JP2013532655A/ja active Pending
- 2011-07-22 RU RU2013107759/04A patent/RU2013107759A/ru not_active Application Discontinuation
- 2011-07-22 BR BR112013001534A patent/BR112013001534A2/pt not_active IP Right Cessation
- 2011-07-22 TW TW100126056A patent/TW201206442A/zh unknown
-
2013
- 2013-01-23 US US13/747,862 patent/US20130137691A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130137691A1 (en) | 2013-05-30 |
| CA2806271A1 (en) | 2012-01-26 |
| SG187564A1 (en) | 2013-03-28 |
| BR112013001534A2 (pt) | 2016-05-10 |
| TW201206442A (en) | 2012-02-16 |
| AU2011281173A1 (en) | 2013-02-07 |
| EP2595970B1 (en) | 2015-01-07 |
| RU2013107759A (ru) | 2014-08-27 |
| MX2013000907A (es) | 2013-03-05 |
| WO2012011081A1 (en) | 2012-01-26 |
| EP2595970A1 (en) | 2013-05-29 |
| FR2963005A1 (fr) | 2012-01-27 |
| KR20130041127A (ko) | 2013-04-24 |
| UY33528A (es) | 2012-02-29 |
| FR2963005B1 (fr) | 2012-08-17 |
| JP2013532655A (ja) | 2013-08-19 |
| CN103201271A (zh) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088021A1 (es) | Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica | |
| ES2624795T3 (es) | Derivados de N-(heteroaril)-1-heteroaril-1H-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| CO6280509A2 (es) | Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica | |
| PA8813101A1 (es) | Derivados bicílicos de carboxamidas aza-bicíclicas,su preparación y su aplicación terapéutica | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| AR091159A1 (es) | Derivados de pirrolo[2,3-b]piridina y sintesis de los mismos | |
| PE20141372A1 (es) | Nuevos derivados dihidroquinolina-2-ona | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| AR066171A1 (es) | Derivados de nicotinamida, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y usos en la prevencion y/o tratamiento del cancer. | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR103199A1 (es) | N-alquilaril-5-oxiaril-octahidrociclopenta[c]pirrol moduladores alóstericos negativos de nr2b | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR075177A1 (es) | Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. | |
| AR088596A1 (es) | Compuestos de bencilamina sustituidos | |
| ECSP13012990A (es) | Derivados de pirazolidin-3-ona | |
| AR091499A1 (es) | Derivados de pirimidinonas, su preparacion y su aplicacion en terapeutica | |
| CO6220956A2 (es) | Derivados de pirazolona como inhibidores de pde4 | |
| NI201200176A (es) | Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |